



Applied BioMath

Selected Presentations and Posters

Year	Event	Partner	Disease	Modality	Title
2016	AACR	Jounce	Oncology	Bispecific	Quantitative Systems Pharmacology (QSP) modeling and analysis provides biological insights into anti-PD-1 dosing and predicts optimal PD-1 x TIM-3 therapeutic properties for bispecifics and fixed dose combinations in I/O (<i>poster</i>)
2016	World ADC	None	Oncology	ADC	Computational Exploration of Mechanistic Determinants of ADC Pharmacokinetics Using QSP Modeling Strategies (<i>poster</i>) *BEST POSTER AWARD*
2017	AACR	Jounce	Oncology	mAb	Preclinical Assessment of JTX-2011, An Agonist Antibody Targeting ICOS, Supports Evaluation In ICONIC Clinical Trial (<i>presentation</i>)
2018	ASCPT	CytomX	Oncology	ADC	QSP Model for the Rational Design and Clinical Translation of a Masked, Tumor-Activated Antibody (<i>poster</i>)
2018	Webinar	Alexion	Rare disease/Liver	LNP-mRNA	A Lipid Nanoparticle QSP Case Study (<i>presented by Pratap Singh, Director of Pharmacometrics and Quantitative Clinical Pharmacology, Alexion</i>)
2018	ACoPg	Shire	Rare disease/Eye	Small molecule	QSP Models Predict Optimal Drug Properties and Inform Translation from Mice to Human in Retinal Degenerative Disease (<i>poster</i>)
2018	ACoPg	Takeda	Slow transit constipation	Small molecule	A QSP Model of Colonic Motility to Aid Drug Discovery and Development (<i>poster</i>)
2018	ACoPg	Novartis	Oncology	mAb	QSP Model of Glucocorticoid-Induced TNFR-Related Protein (GITR)-Medicated T Cell Dynamics in Mouse Tumor Micro Environment (<i>poster</i>)
2018	PharmSci	None	Oncology	mAb	Inferring Target Occupancy from Fitting Nonlinear-PK Data with Mechanistic PKRO Model for Pembrolizumab (<i>poster</i>) *BEST ABSTRACT AWARD*
2018	Webinar	AbbVie	Osteoarthritis	Bispecific	QSP Approaches to Determine Best in Class Properties for Targeted Anabolic Growth Factor to Arthritic Joints (<i>presented by Raj Kamath, Proj. Director, AbbVie</i>)
2018	SITC	Xencor	Oncology	Fusion protein	An IL15/IL15R α heterodimeric Fc-fusion engineered for reduced potency demonstrates an optimal balance of in vivo activity and exposure (<i>poster</i>)
2019	ICI Boston	Novartis	Oncology	mAb	Model Aided Drug Invention Case Study: GITR-mediated T cell Dynamics in Mouse Tumor Micro Environment (<i>presentation</i>)
2019	AACR	Pfizer	Oncology	mAb	A semi-mechanistic platform model to capture individual animal responses to checkpoint inhibitors in a syngeneic mouse model (<i>poster</i>)
2019	AACR	Sanofi	Oncology	mRNA	Development of a multiscale QSP model to characterize the tumor suppressive effects of a cytokine mRNA immunotherapy in a preclinical melanoma mouse model (<i>poster</i>)
2019	AALC	NIH grant	Alzheimer's	mAb/ sm molc	Mechanistic Mathematical Model of the Impact of Anti-Amyloid Beta Drugs and BACE Inhibitors in Alzheimer's Disease (<i>presentation</i>)
2019	World Bispecific	Zymeworks	Oncology	Bispecific	Utilizing QSP Modeling to Inform Clinical and Nonclinical Development of Zymeworks' Azymetric™ Biparatopic Platforms: PK/PD Modeling and Therapeutic Index Estimation (<i>presentation</i>)
2019	World Bispecific	Sanofi	Autoimmune	Bispecific	Model-Based Approach to Design Bi-Specific Modalities in Early Discovery (<i>presentation</i>)
2019	World Bispecific	Revitope	Oncology	Bispecific	The Next Generation of T-Cell Redirecting Antibodies (<i>presentation</i>)
2019	ACoP10	Pfizer	Oncology	mAb	A population QSP model to capture individual tumor growth inhibition responses to anti-CTLA4 therapy in CT26 syngeneic mouse model (<i>poster</i>)
2019	ACoP10	Biogen	Alzheimer's	mAb	A QSP model for Abeta pathway to predict effect of aducanumab on Abeta SUVR change (<i>poster</i>)
2019	SITC	Checkpoint	Oncology	mAb	Semi-mechanistic PK and target-occupancy modeling to support dose justification for anti-PD-L1 clinical candidate CK-301 (TG-1501) in oncology patients (<i>poster</i>)